SS-31 (Elamipretide) vs Vesilute
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
SS-31 (Elamipretide)Anti-Aging & Longevity
Vesilute- Summary
- SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
- Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
- Half-Life
- ~2–5 hours
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5–10 mg
- 10 mg per day
- Frequency
- Daily to several times per week
- Daily for 10–30 days
- Key Benefits
- Restores mitochondrial function and ATP production
- Protects inner mitochondrial membrane cardiolipin
- Reduces mitochondrial reactive oxygen species (ROS)
- Improves exercise capacity and reduces fatigue
- Cardioprotective — studied in heart failure trials
- Renoprotective — reduces ischemic kidney injury
- Anti-aging via mitochondrial preservation
- Potential in neurodegenerative disease prevention
- Supports retinal photoreceptor cell function and survival
- May slow progression of age-related macular degeneration
- Reduces retinal cell apoptosis from oxidative stress and aging
- Anti-aging effects on retinal pigment epithelium
- Potential support in diabetic retinopathy management
- Preserves visual acuity with aging
- Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
- Side Effects
- Injection site irritation
- Nausea (rare)
- Generally well-tolerated in clinical trials
- Generally well tolerated
- Mild injection site reactions
- No significant ocular adverse events reported at standard doses
- Stacks With
- —
- —